Trials / Completed
CompletedNCT00604708
Immunogenicity Study of the Japanese Encephalitis Vaccine IC51
Observer Blinded, Randomized Phase 3 Study to Investigate the Non-Inferiority of IC51 vs. JE-VAX as Vaccines for Japanese Encephalitis in Healthy Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 867 (actual)
- Sponsor
- Valneva Austria GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objective is to demonstrate the non-inferiority of the Japanese Encephalitis vaccine IC51 compared to JE-VAX in healthy subjects aged \> or = 18 years
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IC51 | IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28 |
| BIOLOGICAL | JE-VAX | JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28 |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2006-09-01
- Completion
- 2006-09-01
- First posted
- 2008-01-30
- Last updated
- 2024-03-21
- Results posted
- 2012-11-29
Source: ClinicalTrials.gov record NCT00604708. Inclusion in this directory is not an endorsement.